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Abstract
Background: Ichthyosis Prematurity Syndrome (IPS) is an autosomal recessive disorder characterized by premature
birth, non-scaly ichthyosis and atopic manifestations. The disease was recently shown to be caused by mutations in
the gene encoding the fatty acid transport protein 4 (FATP4) and a specific reduction in the incorporation of very
long chain fatty acids (VLCFA) into cellular lipids.
Findings: We screened probands from five families segregating IPS for mutations in the FATP4 gene. Four
probands were compound heterozygous for four different mutations of which three are novel. Four patients were
heterozygous and one patient homozygous for the previously reported non-sense mutation p.C168X (c.504c > a).
All patients had clinical characteristics of IPS and a similar clinical course.
Conclusions: Missense mutations and non-sense mutations in FATP4 are associated with similar clinical features
suggesting that missense mutations have a severe impact on FATP4 function. The results broaden the mutational
spectrum in FATP4 associated with IPS for molecular diagnosis of and further functional analysis of FATP4.
Introduction
I c h t h y o s i sp r e m a t u r i t ys y n d r o m e( I P S )i sar a r ef o r mo f
autosomal recessive ichthyosis characterized by polyhy-
dramnion and premature birth of the affected child
[1-3]. Newborns exhibit respiratory complications and a
thick caseous desquamating epidermis. During the first
months of life the symptoms become gradually milder.
Patients suffer from a lifelong non-scaly ichthyosis with
atopic manifestations. Ultrastructural analyses reveal
membrane aggregations in the upper epidermal layers,
and histological analysis of the skin reveal thickening of
the epidermis. Patients with IPS have been reported
from Scandinavia, Middle East, southern Europe and
Africa [2,4,5]. However, IPS is more prevalent in
Norway and Sweden with an estimated local carrier fre-
quency of one in 50 suggesting a founder mutation [1].
Linkage and haplotype analysis followed by candidate
gene sequencing of IPS patients have shown that the
disease is associated with mutations in the fatty acid
transport protein 4 (FATP4)g e n e[ 2 ] .T h eF A T P 4p r o -
tein plays a central role in the transport and activation of
fatty acids in the epidermis and for normal epidermal
barrier function [6,7]. The FATP4 gene consists of 13
exons encoding a peptide with a predicted size of 72 kDa
spanning a N-terminal transmembrane (TM) domain, an
endoplasmatic reticulum localization signal (ERx)
domain, ATP/AMP and FATP motifs of AMP-binding
domain [6]. The FATP domains are involved in binding
and uptake of long chain fatty acids (LCFA) and very
long chain fatty acids (VLCFA) as well as catalysis and
esterification of fatty acids in the presence of CoA [6-9].
So far, eight distinct FATP4 mutations have been
reported in IPS patients. One nonsense mutation,
p.C168X, five missense mutations p.A92T, p.S247P,
p.Q300R, p.R374C and p.R583 H, and two splice site
mutations, c.716-1ag > aa and c.988-2ag > gg [2,10].
The p.C168X nonsense variant is prevalent in the Scan-
dinavian IPS population and all patients from this geo-
graphical region were found homozygous or compound
heterozygous for this mutation. In order to clarify the
mutation spectrum in IPS we screened five non-related
probands of Scandinavian descent for novel FATP4
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FATP4 mutations in these probands including three
novel mutations. All six patients were compound het-
erozygous or homozygous for the p.C168X mutation
which further illustrates the high prevalence for this
mutation in the northern European population.
Methods
Patient material
We analyzed six cases with a typical IPS phenotype. The
patients belongs to five families from Norway (IR85,
IR125, and 25187), Denmark (DA1 comprising two
affected siblings) and Iceland (25291; Table 1). No consan-
guinity was reported among parents and no families were
inter-connected through the last four generations. The
patients had a medical history with the clinical triad of
premature birth, thick caseous desquamating epidermis,
and neonathal asphyxia, typical for the IPS phenotype [11].
With the exception of Family DA1 (Figure 1a), no family
history of IPS was recorded. Blood samples were obtained
from probands and from healthy parents and siblings in
three families (Family DA1, IR85 and IR125; Figure 1a).
Mutational analysis
Sequence analysis of the FATP4 gene was initially per-
formed on the probands. In families DA1, IR85 and IR125,
available parents and siblings were included for the inves-
tigation of mutational inheritance (Figure 1a). In total, 16
individuals (six patients and ten relatives) were included in
the mutation analysis. DNA samples from 100 unrelated
healthy Scandinavian control individuals were also ana-
lyzed to rule out polymorphic variants. Bidirectional
sequence analysis of genomic DNA included all 13 exons
of the FATP4 gene as well as intron-exon boundaries, 5’
and 3’ UTRs. Primer sequences used for amplification
were designed with Primer 3 software (primer sequences
available upon request). Sequencing was performed on
an ABI 3730 DNA Analyzer (Applied Biosystems)
using Big Dye Terminator v3.1 Cycle Sequencing
Chemistry (Applied Biosystems) according to protocols
recommended by the manufacturer. Base calling was per-
formed with Sequencing Analysis v 5.2 (Applied Biosys-
tems) and the sequences were analyzed with the
Sequencher software v4.1 (Gene Codes Corporation).
Structural modelling
To analyze the degree of conservation of the predicted
amino acid substitutions, multiple sequence alignment
was performed using ClustalW [12]. The human (Homo
sapiens) FATP4 protein sequence was compared to
mouse (Mus musculus)a n dd o g( Canis familiaris)a s
well as the other members of the FATP protein family
(FATP1, FATP2, FATP3, FATP5 and FATP6)
Results
Mutational analysis
Sequence analysis of the FATP4 gene revealed two
sequence variants predicted to be associated with IPS in
each proband. In total five different mutations were
identified (Table 1). Five probands were compound het-
erozygous for the previously reported c.504c > a transi-
tion in exon 3. This variant predicts the previously
reported p.C168X nonsense mutation. One proband
from the Icelandic family 25291 was found homozygous
for this mutation. We also identified a novel c.103g > t
transition in exon 2. This variant results in a p.G35X
nonsense mutation (Figure 1b) and an early truncation
of the protein. Another three sequence variants were
predicted to result in missense mutations. The p.Q300R
is caused by an a to g transition at nucleotide 899
(c.899g > a) in exon 7 and results in the substitution of
the polar uncharged hydrophilic amino acid glutamine
for the positively charged hydrophilic arginine. This
mutation has been reported previously [2]. The novel
p.V477 D is caused by a t to a transition at nucleotide
1430 (c.1430t > a) in exon 10 and results in the change
of the nonpolar hydrophobic amino acid valine to the
negatively charged hydrophilic aspartic acid. The p.R504
H mutation is another novel variant caused by a g to a
transition at nucleotide 1511 (c.1511g > t) in exon 11
Table 1 Mutations in the FATP4 gene identified in probands from five IPS families
Patient family ID Exon Nucleotide change Amino-acid change Zygosity Origin
IR85 exon3
exon7
c.504c>a
c.899a > g
p.C168X*
p.Q300R*
compound heterozygous Norway
IR125 exon2
exon3
c.103g>t
c.504c > a
p.G35X
p.C168X*
compound heterozygous Norway
25187 exon3
exon10
c.504c>a
c.1430t > a
p.C168X*
p.V477D
compound heterozygous Norway
25291 exon3 c.504c > a p.C168X* homozygous Iceland
DA1 exon3
exon11
c.504c>a
c.1511 g > a
p.C168X*
p.R504H
compound heterozygous Denmark
Family origin and zygosity of the identified mutations. The nucleotide and amino-acid change is indicated and the corresponding exon. *denotes previously
published in Klar et al 2009.
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Page 2 of 4and results in the substitution of the positively charged
hydrophilic arginine for the similarly positively charged
hydrophilic histidine (Table 1). Healthy family members
were available in family IR85, IR125 and DA1 and the
analysis showed that the mutations segregated with
the disease with parents being heterozygous carriers for
the respective mutations (Figure 1a). The three missense
mutations (p.Q300R, p.V477 D and p.R504H) were situ-
ated in the highly conserved AMP-binding domain (aa
103-536). The p.Q300R is situated in the AMP/AMP
motif involved in ATP binding and adenylate formation,
and the novel p.R504 H is located in the FATP motif
important for fatty acid binding (Figure 1c). All variants
were excluded as common variants or polymorphisms
by comparing to databases (dbSNP 131) and by the ana-
lysis of 200 Scandinavian control chromosomes. Thus,
among five different IPS associated mutations identified
in the five families, the p.G35X, p.V477 D and p.R504 H
mutations are novel whereas the two mutations
(p.C168X and p.Q300R) were described previously [2].
Structural modelling
Multiple sequence alignmento ft h eF A T P 4p r o t e i nw a s
performed in order to estimate inter-species conservation
of certain segments and to identify regions shared with
other members of the FATP family of proteins.
Figure 1 Family pedigrees, mutation traces and positions of predicted amino acid substitutions in FATP4. Multiple sequence alignment
is shown of FATP4 protein with orthologs from different species and with the FATP family of proteins. (a) Pedigrees of three of the five families
from which healthy family members were available showing the segregation of mutations and IPS (b) Sequence chromatograms of the five
mutations identified (c) Schematic overview of FATP4 functional domains; the N-terminal transmembrane region (TM), the ER localization signal
(ERx; aa 47-102), the ATP/AMP motif involved in ATP binding and adenylate formation (ATP/AMP; aa 243-345) and the conserved FATP motif of
importance for fatty acid binding (FATP; aa 500-551). The arrows indicate positions of the mutated amino acid residues reported herein
associated with IPS (d) Multiple sequence alignment of selected regions of the human FATP4 protein and Fatp4 proteins from mouse and dog.
Arrows indicate the position of the missense mutations at conserved residues (e) Multiple sequence alignment of FATP4 protein with the human
FATP family of proteins (FATP1, FATP2, FATP3, FATP5, and FATP6). The positions of the missense mutations are indicated by arrows.
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(Homo sapiens), mouse (Mus musculus)a n dd o g( Canis
familiaris) demonstrated strong conservation of the three
amino acids corresponding to the missense mutations in
the patients (Figure 1d). Alignment of the FATP4
sequence to other members of the FATP family of pro-
teins showed complete identity of the amino acids corre-
sponding to the novel missense mutations, p.V477 and
p.R504 (Figure 1e). The previously identified missense
mutation, p.Q300R, is situated in a protein domain
shared exclusively with FATP1.
Discussion
In this study we report on five families from Scandinavia
with members affected by IPS. Sequence analysis
revealed five different mutations, of which three are
novel and two (p.C168X and p.Q300R) have been
reported previously [2]. All patients were either homozy-
gous or compound heterozygous for the nonsense muta-
tion p.C168X, confirming this to be a prevalent ancestral
mutation in the Scandinavian population. The novel var-
iants include one nonsense (p.G35X) and two novel mis-
sense mutations (p.V477 D and p.R504H) in our cohort
of patients. Both missense mutations are situated in the
highly conserved AMP binding domain of the FATP4
protein supporting their functional significance. The
p.R504 H mutation is also the first mutation described
in the FATP motif within this domain. The functional
significance of this mutation is supported by studies of
the FATP1 member of the FATP family of proteins
demonstrating that mutations in the FATP motif results
in an almost complete elimination of both transport and
activation of fatty acids [13].
Conclusions
With the exception of the ancestral p.C168X mutation, the
IPS associated mutational spectrum in FATP4 appear het-
erogeneous and with a predilection to functional FATP
domains. However, from our observations there appear to
be no obvious correlations between the nature of muta-
tions in the FATP4 protein and the IPS phenotype. This
suggests that the missense mutations reported herein have
deleterious effects on FATP4 function which are similar to
the effects of the nonsense mutations. Our findings also
confirm the critical role of FATP4 for the development
and maintenance of the skin barrier. Furthermore, this
study adds to the mutational spectrum associated with
IPS, which may improve genetic diagnosis of the disease
as well as future functional analysis of FATP4.
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